ConditionStroke
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorThe George Institute
About this trial
Stroke is causing 6.6 million deaths and is a major cause of disability worldwide in 2019. There remains an urgent need for interventions that improve outcomes which can be implemented with wide applicability for stroke. ACT-GLOBAL is a multi-factorial, multi-arm, multi-stage, randomised, global adaptive platform trial for stroke, aiming to identify the treatment/s associated with the highest chance of improving outcome in stroke patients. In ACT-GLOBAL multiple questions will be evaluated simultaneously and sequentially as data accrues and can evaluate interactions between different treatment options.
Eligibility criteria
Qualifiers
Age ≥18 years
Clinical diagnosis of stroke
Disqualifiers
None
Trial design
Treatments tested in this trial
- Standard-dose intravenous tenecteplase
- Low-dose intravenous tenecteplase
- No intravenous tenecteplase
- Conservative Blood Pressure Control
- Moderate Blood Pressure Control
- Intensive Blood Pressure Control
- Placebo
- NoNO-42
- No deferoxamine mesylate and no colchicine
- Deferoxamine mesylate only
- Colchicine only
- Both deferoxamine mesylate and colchicine
Treatment groups
20,000 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov